Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1643 1645 1652
This examiner grants 50% of resolved cases
Jieun Ham is an examiner in Tech Center 1600, specifically within Art Unit 1600. The examiner has 8 resolved cases, which is a relatively small sample size for statistical analysis. The allowance rate is 50.0 percent, indicating the current frequency of patent grants for applications reaching a final disposition. This 50.0 percent rate provides a neutral starting point for practitioners assessing their chances of success in this art unit.
The median days to allowance for these cases is 1073. This timeline suggests that the prosecution process for successful applications typically lasts for a significant duration. The interview lift percentage is 8.8, indicating that interviews have a positive impact on the likelihood of allowance. While the 50.0 percent allowance rate is based on 8 resolved cases, the 8.8 percent lift suggests that engaging with the examiner can be a helpful step in the process. Practitioners in Tech Center 1600 should account for the 1073-day median pendency when planning their prosecution timelines. As the examiner handles more cases, these figures will provide a clearer picture of the long-term trends in Art Unit 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18565831 | METHODS OF USING ANTI-CD83 CHIMERIC ANTIGEN RECEPTOR EXPRESSING T CELLS | Non-Final OA | Regents of the University of Minnesota |
| 17773658 | SMALL LIPID NANOPARTICLES, AND CANCER VACCINE INCLUDING SAME | Non-Final OA | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18699702 | ENGINEERING NK CELLS WITH A CAR CONSTRUCT WITH OPTIMAL SIGNALING | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17611019 | METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER | Non-Final OA | Board of Regents, The University of Texas System |
| 18698343 | TREATMENT OF LUPUS | Non-Final OA | ASTRAZENECA AB |
| 18033777 | ENGINEERED NK CELLS | Non-Final OA | City of Hope |
| 18420883 | COMBINATIONS FOR TREATING CANCER | Non-Final OA | Purdue Pharma L.P. |
| 18300302 | ANTIBODIES THAT BIND PD-L1, PD-L2, AND/OR CD28 | Non-Final OA | Xencor, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy